Q3 Earnings Forecast for GRDN Issued By KeyCorp

Guardian Pharmacy Services, Inc. (NYSE:GRDN) – Investment analysts at KeyCorp issued their Q3 2026 EPS estimates for Guardian Pharmacy Services in a research note issued on Tuesday, September 22nd. KeyCorp analyst Z. Haggerty forecasts that the company will post earnings per share of $0.27 for the quarter. KeyCorp has a “Overweight” rating and a $52.00 price target on the stock. The consensus estimate for Guardian Pharmacy Services’ current full-year earnings is $1.19 per share. KeyCorp also issued estimates for Guardian Pharmacy Services’ Q4 2026 earnings at $0.36 EPS, FY2026 earnings at $1.16 EPS, Q1 2027 earnings at $0.28 EPS, Q2 2027 earnings at $0.28 EPS, Q3 2027 earnings at $0.30 EPS, Q4 2027 earnings at $0.40 EPS, FY2027 earnings at $1.27 EPS and FY2028 earnings at $1.46 EPS.

Several other analysts have also weighed in on the stock. Wall Street Zen lowered shares of Guardian Pharmacy Services from a “buy” rating to a “hold” rating in a research note on Saturday, September 19th. Oppenheimer increased their target price on shares of Guardian Pharmacy Services from $43.00 to $49.00 and gave the stock an “outperform” rating in a research note on Friday, August 7th. Weiss Ratings raised shares of Guardian Pharmacy Services from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, August 20th. Bank of America upped their price objective on shares of Guardian Pharmacy Services from $42.00 to $47.00 and gave the company a “buy” rating in a report on Wednesday, June 17th. Finally, Truist Financial increased their price objective on shares of Guardian Pharmacy Services from $47.00 to $51.00 and gave the stock a “buy” rating in a research report on Monday. Nine research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $45.57.

Guardian Pharmacy Services Stock Performance

Shares of GRDN opened at $41.77 on Friday. Guardian Pharmacy Services has a 52-week low of $23.14 and a 52-week high of $48.33. The business’s 50 day moving average price is $40.76 and its two-hundred day moving average price is $39.19. The firm has a market cap of $2.08 billion, a PE ratio of 40.55, a price-to-earnings-growth ratio of 2.31 and a beta of 0.06.

Guardian Pharmacy Services (NYSE:GRDN) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.29 EPS for the quarter, beating analysts’ consensus estimates of $0.26 by $0.03. Guardian Pharmacy Services had a net margin of 4.50% and a return on equity of 29.97%. The business had revenue of $351.77 million for the quarter, compared to analysts’ expectations of $340.45 million.

Institutional Investors Weigh In On Guardian Pharmacy Services

Hedge funds have recently made changes to their positions in the business. Clearstead Advisors LLC grew its position in Guardian Pharmacy Services by 196.3% during the fourth quarter. Clearstead Advisors LLC now owns 2,628 shares of the company’s stock valued at $79,000 after buying an additional 1,741 shares during the period. Elevation Point Wealth Partners LLC bought a new position in shares of Guardian Pharmacy Services during the 1st quarter valued at approximately $253,000. Stephens Inc. AR purchased a new stake in shares of Guardian Pharmacy Services during the 1st quarter worth approximately $282,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Guardian Pharmacy Services in the 2nd quarter worth approximately $335,000. Finally, Arizona State Retirement System raised its holdings in shares of Guardian Pharmacy Services by 53.0% in the 2nd quarter. Arizona State Retirement System now owns 8,393 shares of the company’s stock worth $351,000 after purchasing an additional 2,907 shares during the period.

Trending Headlines about Guardian Pharmacy Services

Here are the key news stories impacting Guardian Pharmacy Services this week:

• Positive Sentiment: KeyCorp initiated coverage of Guardian Pharmacy Services with an Overweight rating and a $52 price target, indicating confidence in the company’s growth prospects and potential upside. KeyBanc initiates coverage of Guardian Pharmacy Services at overweight
• Positive Sentiment: KeyCorp projected EPS of $1.27 for fiscal 2027 and $1.46 for fiscal 2028, compared with $1.16 for fiscal 2026, signaling expectations for continued earnings growth. Its quarterly forecasts range from $0.28 to $0.40 per share through 2027. Guardian Pharmacy Services Stock Rated Overweight in New Coverage at KeyCorp
• Neutral Sentiment: The multiple reports released by KeyCorp largely repeat the same rating, target price and EPS estimates rather than representing separate analyst upgrades or new company announcements. The current-year consensus EPS estimate remains $1.19.
• Negative Sentiment: KeyCorp’s $1.16 fiscal 2026 EPS forecast is modestly below the $1.19 consensus estimate, which may have tempered the market’s reaction. The stock also trades at a relatively elevated trailing P/E of about 40.6, leaving less room for disappointment even with the longer-term earnings growth outlook.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc is a long-term care pharmacy company that provides prescription medications and related pharmacy services to residents of assisted living communities, skilled nursing facilities, memory care centers and other institutional care settings.

The company’s services include medication dispensing and packaging, prescription delivery, medication management, pharmacy consulting and clinical support. Guardian works with care providers, residents and their families to help coordinate medication regimens, improve adherence and support the ongoing pharmacy needs of patients who may require complex or recurring treatments.

Guardian Pharmacy Services operates through a network of community-based pharmacies serving long-term care customers in multiple U.S.